Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Clinical importance of high-mannose, fucosylated, and complex N-glycans in breast cancer metastasis
Klára Ščupáková, … , Ron M.A. Heeren, Kristine Glunde
Klára Ščupáková, … , Ron M.A. Heeren, Kristine Glunde
Published November 9, 2021
Citation Information: JCI Insight. 2021;6(24):e146945. https://doi.org/10.1172/jci.insight.146945.
View: Text | PDF
Resource and Technical Advance Oncology

Clinical importance of high-mannose, fucosylated, and complex N-glycans in breast cancer metastasis

  • Text
  • PDF
Abstract

BACKGROUND. Although aberrant glycosylation is recognized as a hallmark of cancer, glycosylation in clinical breast cancer (BC) metastasis has not yet been studied. While preclinical studies show that the glycocalyx coating of cancer cells is involved in adhesion, migration, and metastasis, glycosylation changes from primary tumor (PT) to various metastatic sites remain unknown in patients. METHODS. We investigated N-glycosylation profiles in 17 metastatic BC patients from our rapid autopsy program. Primary breast tumor, lymph node metastases, multiple systemic metastases, and various normal tissue cores from each patient were arranged on unique single-patient tissue microarrays (TMAs). We performed mass spectrometry imaging (MSI) combined with extensive pathology annotation of these TMAs, and this process enabled spatially differentiated cell-based analysis of N-glycosylation patterns in metastatic BC. RESULTS. N-glycan abundance increased during metastatic progression independently of BC subtype and treatment regimen, with high-mannose glycans most frequently elevated in BC metastases, followed by fucosylated and complex glycans. Bone metastasis, however, displayed increased core-fucosylation and decreased high-mannose glycans. Consistently, N-glycosylated proteins and N-glycan biosynthesis genes were differentially expressed during metastatic BC progression, with reduced expression of mannose-trimming enzymes and with elevated EpCAM, N-glycan branching, and sialyation enzymes in BC metastases versus PT. CONCLUSION. We show in patients that N-glycosylation of breast cancer cells undergoing metastasis occurs in a metastatic site–specific manner, supporting the clinical importance of high-mannose, fucosylated, and complex N-glycans as future diagnostic markers and therapeutic targets in metastatic BC. FUNDING. NIH grants R01CA213428, R01CA213492, R01CA264901, T32CA193145, Dutch Province Limburg “LINK”, European Union ERA-NET TRANSCAN2-643638.

Authors

Klára Ščupáková, Oluwatobi T. Adelaja, Benjamin Balluff, Vinay Ayyappan, Caitlin M. Tressler, Nicole M. Jenkinson, Britt S.R. Claes, Andrew P. Bowman, Ashley M. Cimino-Mathews, Marissa J. White, Pedram Argani, Ron M.A. Heeren, Kristine Glunde

×

Figure 1

Overview of study design and analysis strategy.

Options: View larger image (or click on image) Download as PowerPoint
Overview of study design and analysis strategy.
(A) Schematic layout of ...
(A) Schematic layout of TMA #12. Each of the 17 TMAs consisted of 99 cores, with 9 cores of control tissue and 4–5 cores per tumor. BPT, breast primary tumor; BTT, breast treated tumor; CTRL, control; Mets, metastasis; NL, normal; Ax, axilliary; Abd, Abdominal; LN, lymph node; Diaphr, diaphragm; Medias, mediastinum. Pink circle denotes the sample shown in C. (B) MALDI-MSI data of TMA #12 at a spatial resolution of 50 μm per pixel. The m/z 1257.5 map is overlaid with pathological annotations, demonstrating differential abundance between different annotated organ sites. (C) Detailed histological annotation of representative breast PT core (left) coregistered with MSI data (right): 1, normal tissue; 2, cancer; 3, cancer mixed with cancer-associated stroma; 4, cancer mixed with lymphoplasmacytic infiltrate; and 5, cancer-associated stroma. Blue lines are for normal, red for cancerous tissue, and green for stroma. (D) Identification of m/z values of interest from all 17 TMAs was performed using GlycoWorkbench 2.1 software with GlycomeDB database. In this example, m/z 1257.56 ± 0.3 Da was identified as Hex5HexNAc2.

Copyright © 2022 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts